
- 100 free trades signup offer
- Easy-to-use platform
- Low fees
- Student and young investor discounts
Medicenna Therapeutics Corp is a biotechnology business based in Canada. Medicenna Therapeutics Corp shares (MDNA) are listed on the Toronto Stock Exchange (TSX) and all prices are listed in Canadian Dollars.
Its last market close was C$1.10 – an increase of 11.11% over the previous week. Medicenna Therapeutics Corp employs 16 staff and has a market cap (total outstanding shares value) of 0.00.Note: The dollar amounts in the table below are in Canadian dollars.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.
Latest market close | C$1.10 |
---|---|
52-week range | C$0.89 - C$2.98 |
50-day moving average | C$1.24 |
200-day moving average | C$1.85 |
Wall St. target price | C$4.38 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | C$-0.37 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of C$1.09 from 2025-03-13
1 week (2025-03-07) | 10.10% |
---|---|
1 month (2025-02-14) | -18.66% |
3 months (2024-12-13) | -38.42% |
6 months (2024-09-13) | -47.60% |
1 year (2024-03-14) | -30.57% |
---|---|
2 years (2023-03-14) | 37.97% |
3 years (2022-03-14) | 1.62 |
5 years (2020-03-13) | 3.07 |
Gross profit TTM | C$0 |
---|---|
Return on assets TTM | -42.08% |
Return on equity TTM | -149.09% |
Profit margin | 0% |
Book value | C$0.22 |
Market Capitalization | C$86 million |
EBITDA | C$-18,673,000 |
TTM: trailing 12 months
We're not expecting Medicenna Therapeutics Corp to pay a dividend over the next 12 months.
Medicenna Therapeutics Corp's stocks were split on a 1:14 basis on 2 March 2017 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Medicenna Therapeutics Corp stocks – just the quantity. However, indirectly, the new 1300% higher stock price could have impacted the market appetite for Medicenna Therapeutics Corp stocks, which in turn could have impacted Medicenna Therapeutics Corp's stock price.
Over the last 12 months, Medicenna Therapeutics Corp's stocks have ranged in value from as little as C$0.89 up to C$2.98. A popular way to gauge a stock's volatility is its "beta."
Beta is a measure of a stocks volatility in relation to the market. The market (TO average) beta is 1, while Medicenna Therapeutics Corp's is 1.083. This would suggest that Medicenna Therapeutics Corp's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada..
Want to dive into investing but don’t have much to spend? Take a look at these types of stocks.
Read more…Meme stocks can produce large gains in short periods, but the stocks are volatile.
Read more…Your guide to how ETFs work and whether this type of investment is right for you.
Read more…Steps to buying Coinbase stock in Canada with 24-hour and historical pricing before you buy.
Find out how the Trump tariffs will impact the stock market and explore Canadian stocks that may be resilient amidst tariffs.
Enjoy perks like free trades and cash back when you open a stock trading account with these online broker promotions.
Here’s our methodology for scoring the features that matter, and picking the top stock trading platforms in Canada.
These are the best renewable energy stocks to buy now in Canada.
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
Whether you’re a new or experienced investor, these are the best stock trading platforms and apps in Canada.
Buying US stocks in Canada is easier than you think. Find out how to buy US stocks in 4 simple steps.
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.
Questrade is a leader among Canadian discount brokerages, but is it right for you? Compare fees, features and alternatives here.